Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Last update: 10:49 AM
Comments
Loading...
Jasper Therapeutics Analyst Ratings and Price Targets | NASDAQ:JSPR | Benzinga
Jasper Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Jasper Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Evercore ISI Group
JMP Securities
BTIG
UBS
BMO Capital
1calculated from analyst ratings
Analyst Ratings for Jasper Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
09/22/2025 | — | Evercore ISI Group | $20 → $14 | Maintains | Outperform | |||
09/22/2025 | — | JMP Securities | $12 → $6 | Maintains | Market Outperform | |||
09/22/2025 | — | BTIG | $20 → $7 | Maintains | Buy | |||
08/15/2025 | — | UBS | $29 → $25 | Maintains | Buy | |||
07/08/2025 | — | BMO Capital | $15 → $4 | Downgrade | Outperform → Market Perform | |||
07/08/2025 | — | JMP Securities | $70 → $12 | Maintains | Market Outperform | |||
07/08/2025 | — | Evercore ISI Group | $50 → $20 | Maintains | Outperform | |||
07/07/2025 | — | William Blair | — | Downgrade | Outperform → Market Perform | |||
07/07/2025 | — | HC Wainwright & Co. | $40 → $20 | Maintains | Buy | |||
07/07/2025 | — | Cantor Fitzgerald | — | Downgrade | Overweight → Neutral | |||
07/07/2025 | — | BTIG | $64 → $20 | Maintains | Buy | |||
05/15/2025 | — | Oppenheimer | $80 → $65 | Maintains | Outperform | |||
05/13/2025 | — | UBS | $38 → $33 | Maintains | Buy | |||
03/11/2025 | — | HC Wainwright & Co. | $40 → $40 | Reiterates | Buy → Buy | |||
02/13/2025 | — | UBS | → $38 | Initiates | → Buy | |||
01/10/2025 | — | JMP Securities | $70 → $70 | Reiterates | Market Outperform → Market Outperform | |||
01/10/2025 | — | HC Wainwright & Co. | $60 → $40 | Maintains | Buy | |||
01/09/2025 | — | RBC Capital | $68 → $48 | Maintains | Outperform | |||
01/06/2025 | — | JMP Securities | $70 → $70 | Maintains | Market Outperform | |||
12/23/2024 | — | RBC Capital | $68 → $68 | Reiterates | Outperform → Outperform | |||
12/06/2024 | — | BMO Capital | → $63 | Initiates | → Outperform | |||
10/24/2024 | — | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
10/15/2024 | — | JMP Securities | $70 → $70 | Reiterates | Market Outperform → Market Outperform | |||
10/15/2024 | — | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
09/27/2024 | — | JMP Securities | $70 → $70 | Reiterates | Market Outperform → Market Outperform | |||
09/09/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
09/09/2024 | — | JMP Securities | → $70 | Initiates | → Market Outperform | |||
08/26/2024 | — | Evercore ISI Group | $65 → $65 | Maintains | Outperform | |||
08/14/2024 | — | RBC Capital | $70 → $68 | Maintains | Outperform | |||
08/13/2024 | — | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
08/05/2024 | — | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
07/08/2024 | — | BTIG | → $90 | Initiates | → Buy | |||
06/27/2024 | — | Stifel | → $86 | Initiates | → Buy | |||
06/18/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
05/20/2024 | — | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
05/15/2024 | — | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
05/06/2024 | — | HC Wainwright & Co. | → $65 | Initiates | → Buy | |||
04/03/2024 | — | Evercore ISI Group | → $65 | Initiates | → Outperform | |||
03/28/2024 | — | RBC Capital | → $70 | Initiates | → Outperform | |||
03/18/2024 | — | TD Cowen | — | Initiates | → Outperform | |||
03/07/2024 | — | Oppenheimer | $80 → $80 | Maintains | Outperform | |||
10/12/2023 | — | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight | |||
08/14/2023 | — | Credit Suisse | → $4 | Reiterates | Outperform → Outperform | |||
08/11/2023 | — | Capital One | → $7 | Initiates | → Overweight | |||
06/12/2023 | — | EF Hutton | → $6.85 | Reiterates | Buy → Buy | |||
05/25/2023 | — | EF Hutton | → $6.85 | Assumes | → Buy | |||
05/16/2023 | — | Oppenheimer | → $8 | Reinstates | Outperform → Outperform | |||
05/15/2023 | — | EF Hutton | → $6.85 | Reiterates | Buy → Buy | |||
05/15/2023 | — | Credit Suisse | → $4 | Reiterates | Outperform → Outperform | |||
03/09/2023 | — | EF Hutton | → $6.85 | Reiterates | → Buy | |||
03/09/2023 | — | Cantor Fitzgerald | → $6 | Reiterates | → Overweight | |||
03/09/2023 | — | Credit Suisse | → $4 | Reiterates | → Outperform | |||
02/27/2023 | — | EF Hutton | → $6.85 | Reiterates | → Buy | |||
02/21/2023 | — | EF Hutton | → $6.85 | Reiterates | → Buy | |||
02/17/2023 | — | EF Hutton | → $6.85 | Reiterates | → Buy | |||
02/16/2023 | — | EF Hutton | $4 → $6.85 | Maintains | Buy | |||
02/07/2023 | — | Cantor Fitzgerald | $10 → $6 | Reiterates | → Overweight | |||
01/11/2023 | — | Credit Suisse | $7 → $3 | Maintains | Outperform | |||
01/11/2023 | — | EF Hutton | → $4 | Maintains | Buy | |||
11/14/2022 | — | Oppenheimer | $21 → $8 | Maintains | Outperform | |||
11/01/2022 | — | EF Hutton | → $4 | Initiates | → Buy |
FAQ
What is the target price for Jasper Therapeutics (JSPR) stock?
The latest price target for Jasper Therapeutics (NASDAQ:JSPR) was reported by Evercore ISI Group on September 22, 2025. The analyst firm set a price target for $14.00 expecting JSPR to rise to within 12 months (a possible 494.48% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Jasper Therapeutics (JSPR)?
The latest analyst rating for Jasper Therapeutics (NASDAQ:JSPR) was provided by Evercore ISI Group, and Jasper Therapeutics maintained their outperform rating.
When was the last upgrade for Jasper Therapeutics (JSPR)?
There is no last upgrade for Jasper Therapeutics
When was the last downgrade for Jasper Therapeutics (JSPR)?
The last downgrade for Jasper Therapeutics Inc happened on July 8, 2025 when BMO Capital changed their price target from $15 to $4 for Jasper Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Jasper Therapeutics (JSPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jasper Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jasper Therapeutics was filed on September 22, 2025 so you should expect the next rating to be made available sometime around September 22, 2026.
Is the Analyst Rating Jasper Therapeutics (JSPR) correct?
While ratings are subjective and will change, the latest Jasper Therapeutics (JSPR) rating was a maintained with a price target of $20.00 to $14.00. The current price Jasper Therapeutics (JSPR) is trading at is $2.36, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
